Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Giuseppe Visani

Showing results (61-70 of 103) with videos related to

Pageof 11
Sort By:
Frontiers in Oncology|September 24, 2021
Metabolic Switch and Cytotoxic Effect of Metformin on Burkitt LymphomaIrene Bagaloni, Axel Visani, Sara Biagiotti, et al.
Leukemia & Lymphoma|June 30, 2004
Effectiveness of fludarabine, idarubicin and cyclophosphamide (FLUIC) combination regimen for young patients with untreated non-follicular low-grade non-Hodgkin's lymphomaPier Luigi Zinzani, Alessandro Pulsoni, Patrizia Gentilini, et al.
Blood Advances|October 19, 2020
Gene expression profile predicts response to the combination of tosedostat and low-dose cytarabine in elderly AMLGiuseppe Visani, Federica Loscocco, Mike Dennis, et al.
British Journal of Haematology|January 20, 2007
Technetium-99m sestamibi scintigraphy is sensitive and specific for the staging and the follow-up of patients with multiple myeloma: a multicentre study on 397 scansAnna Mele, Massimo Offidani, Giuseppe Visani, et al.
Clinical Lymphoma & Myeloma|October 16, 2008
Serum C-reactive protein at diagnosis and response to therapy is the most powerful factor predicting outcome of multiple myeloma treated with thalidomide/ anthracycline-based therapyMassimo Offidani, Laura Corvatta, Claudia Polloni, et al.
Cancer Research|May 25, 2017
Persistent Immune Stimulation Exacerbates Genetically Driven Myeloproliferative Disorders via Stromal RemodelingClaudio Tripodo, Alessia Burocchi, Pier Paolo Piccaluga, et al.
European Journal of Haematology|March 25, 2010
ThaDD plus high dose therapy and autologous stem cell transplantation does not appear superior to ThaDD plus maintenance in elderly patients with de novo multiple myelomaMassimo Offidani, Pietro Leoni, Laura Corvatta, et al.
Frontiers in Oncology|May 27, 2021
Immunotherapy in Acute Myeloid Leukemia: Where We StandAlessandro Isidori, Claudio Cerchione, Naval Daver, et al.
Clinical Lymphoma, Myeloma & Leukemia|September 18, 2012
Assessment of vulnerability measures and their effect on survival in a real-life population of multiple myeloma patients registered at Marche Region Multiple Myeloma RegistryMassimo Offidani, Laura Corvatta, Claudia Polloni, et al.
Leukemia & Lymphoma|May 26, 2010
Melphalan, prednisone, and thalidomide versus thalidomide, dexamethasone, and pegylated liposomal doxorubicin regimen in very elderly patients with multiple myeloma: a case-match studyMassimo Offidani, Pietro Leoni, Sara Bringhen, et al.
Pageof 11

Showing results (61-70 of 103) with videos related to

Sort By:
Pageof 11
Frontiers in Oncology|September 24, 2021
Metabolic Switch and Cytotoxic Effect of Metformin on Burkitt LymphomaIrene Bagaloni, Axel Visani, Sara Biagiotti, et al.
Leukemia & Lymphoma|June 30, 2004
Effectiveness of fludarabine, idarubicin and cyclophosphamide (FLUIC) combination regimen for young patients with untreated non-follicular low-grade non-Hodgkin's lymphomaPier Luigi Zinzani, Alessandro Pulsoni, Patrizia Gentilini, et al.
Blood Advances|October 19, 2020
Gene expression profile predicts response to the combination of tosedostat and low-dose cytarabine in elderly AMLGiuseppe Visani, Federica Loscocco, Mike Dennis, et al.
British Journal of Haematology|January 20, 2007
Technetium-99m sestamibi scintigraphy is sensitive and specific for the staging and the follow-up of patients with multiple myeloma: a multicentre study on 397 scansAnna Mele, Massimo Offidani, Giuseppe Visani, et al.
Clinical Lymphoma & Myeloma|October 16, 2008
Serum C-reactive protein at diagnosis and response to therapy is the most powerful factor predicting outcome of multiple myeloma treated with thalidomide/ anthracycline-based therapyMassimo Offidani, Laura Corvatta, Claudia Polloni, et al.
Cancer Research|May 25, 2017
Persistent Immune Stimulation Exacerbates Genetically Driven Myeloproliferative Disorders via Stromal RemodelingClaudio Tripodo, Alessia Burocchi, Pier Paolo Piccaluga, et al.
European Journal of Haematology|March 25, 2010
ThaDD plus high dose therapy and autologous stem cell transplantation does not appear superior to ThaDD plus maintenance in elderly patients with de novo multiple myelomaMassimo Offidani, Pietro Leoni, Laura Corvatta, et al.
Frontiers in Oncology|May 27, 2021
Immunotherapy in Acute Myeloid Leukemia: Where We StandAlessandro Isidori, Claudio Cerchione, Naval Daver, et al.
Clinical Lymphoma, Myeloma & Leukemia|September 18, 2012
Assessment of vulnerability measures and their effect on survival in a real-life population of multiple myeloma patients registered at Marche Region Multiple Myeloma RegistryMassimo Offidani, Laura Corvatta, Claudia Polloni, et al.
Leukemia & Lymphoma|May 26, 2010
Melphalan, prednisone, and thalidomide versus thalidomide, dexamethasone, and pegylated liposomal doxorubicin regimen in very elderly patients with multiple myeloma: a case-match studyMassimo Offidani, Pietro Leoni, Sara Bringhen, et al.
Pageof 11